First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Metastatic Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 42 (planned)
- Started
- May 18, 2026
- Main results expected
- Nov 17, 2027
- Fully finished
- Nov 17, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)
Measured over: From time of Informed Consent to 90 days post last dose of study intervention (up to 3 years)
Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)
Measured over: From first study dose to 21 OR 28 days post first dose based on schedule
PSA response rate (Part B only)
Measured over: Up to 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07529717 · record last updated 2026-10-09 · checked 2026-11-09 15:47 UTC